Wissenschaftliche Studien
![](/kontakte_media/Mitarbeiterverzeichnis/Klinik+f%C3%BCr+Innere+Medizin+III/Pfeil_Alexander_2-font-274-height-442-width-290.jpg)
Facharzt für Innere Medizin/Rheumatologie; Osteologe DVO, Notfallmedizin, Fachkunde Leitender Notarzt, Immunologe,
Leiter Sektion und Rheumazentrum (nach GBA-Kriterien)
Indikationsbereich |
EudraCT-Nr. |
Phase |
Studientitel |
Protokollnummer |
Cutaneous Systemic Sclerosis |
2022- 500332-11-00 NCT05559580 |
II |
A Phase II, randomised, placebo-controlled, double-blind, parallel-group efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis |
1366-0031 (VITALISScE) |
GCA |
2021- 002622-24 |
IIIb |
A randomized, parallel-group, double-blind, placebo-controlled, multicenter trial to investigate the efficacy and safety of subcutaneously administered secukinumab in patients with new-onset of giant cell arteritis (GCA) who are in clinical remission and eligible for treatment with glucocorticoid-monotheraphy (GigAINt) |
CAIN457R1DE01 (GigAINt) |
SLE |
2017- 005026-37 |
III |
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus |
I4V-MC-JAHZ |
GCA |
2018- 001003-36 |
II |
A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL-301 in giant cell arteritis |
KPL-301-C001 |
EGPA |
2014- 003162-25 |
III |
Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) |
MEA116841 |
SLE |
2014- 004632-19 |
III |
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus |
D3461C00004 (Tulip II SLE) |
GCA |
2015- 001758-14 |
III |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis |
201677 (Sirresta) |
SLE |
2016- 000625-39 |
III |
A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects with Active Systemic Lupus Erythematosus |
D3461C00009 (Tulip SLE LTE) |
GCA |
2011- 006022-25 |
III |
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF TOCILIZUMAB IN SUBJECTS WITH GIANT CELL ARTERITIS |
WA28119 (GiACTA) |
Ankylosing Spondylitis |
2013- 001090-24 |
III |
A randomized, double-blind, placebo-controlled phase III multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long-term safety, tolerability and efficacy up to 3 years in subjects with active Ankylosing Spondylitis |
CAIN457F2314 |
EPGA |
2012- 004385-17 |
III |
A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy. |
MEA115921 |
Ankylosing Spondylitis |
2010- 024529-18 |
III |
A randomized, double-blind, placebo-controlled, multicenter study of secukinumab to demonstrate the efficacy at 16 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active Ankylosing Spondylitis |
CAIN457F2305 (MEASURE-1) |